Literature DB >> 1932526

Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio.

D W Jones1, I J Mackie, M Winter, M Gallimore, S J Machin.   

Abstract

Laboratory diagnosis of protein C deficiency is complicated by the fact that many patients referred for investigation are already being treated with oral anticoagulants. Protein C and factor VII have similar half lives and by using the protein C:factor VII ratio we hoped to be able to detect protein C deficiency in patients receiving oral anticoagulants. We have studied activity levels of protein C and factor VII to produce protein C:factor VII activity ratios in 105 patients receiving oral anticoagulants, 42 normal subjects, and nine patients with known inherited protein C deficiency. The mean ratios for these groups were 1.38, 1.12 and 0.63 respectively. In patients receiving oral anticoagulants, the protein C level showed a poor correlation with the international normalized ratio (INR) value. Reference ranges for protein C at different levels of anticoagulation were therefore considered unsuitable for the identification of inherited protein C deficiency. Five patients with inherited protein C deficiency were studied with and without oral anticoagulation; their protein C:factor VII ratios remained relatively unchanged, despite alterations in the level of the individual proteins. These results suggest that measurement of the protein C:factor VII ratio may help to identify patients with inherited protein C deficiency whilst on oral anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1932526     DOI: 10.1097/00001721-199106000-00001

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate.

Authors:  F M Müller; W Ehrenthal; G Hafner; D Schranz
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.